🎉 M&A multiples are live!
Check it out!

Caribou Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Caribou Biosciences and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Caribou Biosciences Overview

About Caribou Biosciences

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.


Founded

2011

HQ

United States of America
Employees

147

Website

cariboubio.com

Financials

LTM Revenue $9.7M

LTM EBITDA -$167M

EV

-$109M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Caribou Biosciences Financials

Caribou Biosciences has a last 12-month revenue of $9.7M and a last 12-month EBITDA of -$167M.

In the most recent fiscal year, Caribou Biosciences achieved revenue of $10.0M and an EBITDA of -$163M.

Caribou Biosciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Caribou Biosciences valuation multiples based on analyst estimates

Caribou Biosciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $34.5M $10.0M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$113M -$163M XXX XXX XXX
EBITDA Margin -326% -1628% XXX XXX XXX
Net Profit -$99.4M -$102M XXX XXX XXX
Net Margin -288% -1021% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Caribou Biosciences Stock Performance

As of April 15, 2025, Caribou Biosciences's stock price is $1.

Caribou Biosciences has current market cap of $74.4M, and EV of -$109M.

See Caribou Biosciences trading valuation data

Caribou Biosciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$109M $74.4M XXX XXX XXX XXX $-1.68

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Caribou Biosciences Valuation Multiples

As of April 15, 2025, Caribou Biosciences has market cap of $74.4M and EV of -$109M.

Caribou Biosciences's trades at -11.1x LTM EV/Revenue multiple, and 0.6x LTM EBITDA.

Analysts estimate Caribou Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Caribou Biosciences and 10K+ public comps

Caribou Biosciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$109M XXX XXX XXX
EV/Revenue -10.9x XXX XXX XXX
EV/EBITDA 0.7x XXX XXX XXX
P/E -0.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Caribou Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Caribou Biosciences Valuation Multiples

Caribou Biosciences's NTM/LTM revenue growth is 42%

Caribou Biosciences's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.2M for the same period.

Over next 12 months, Caribou Biosciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Caribou Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Caribou Biosciences and other 10K+ public comps

Caribou Biosciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -71% XXX XXX XXX XXX
EBITDA Margin -1628% XXX XXX XXX XXX
EBITDA Growth 45% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -1586% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 465% XXX XXX XXX XXX
R&D Expenses to Revenue 1302% XXX XXX XXX XXX
Opex to Revenue 1767% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Caribou Biosciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Caribou Biosciences M&A and Investment Activity

Caribou Biosciences acquired  XXX companies to date.

Last acquisition by Caribou Biosciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Caribou Biosciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Caribou Biosciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Caribou Biosciences

When was Caribou Biosciences founded? Caribou Biosciences was founded in 2011.
Where is Caribou Biosciences headquartered? Caribou Biosciences is headquartered in United States of America.
How many employees does Caribou Biosciences have? As of today, Caribou Biosciences has 147 employees.
Who is the CEO of Caribou Biosciences? Caribou Biosciences's CEO is Dr. Rachel Haurwitz, PhD.
Is Caribou Biosciences publicy listed? Yes, Caribou Biosciences is a public company listed on NAS.
What is the stock symbol of Caribou Biosciences? Caribou Biosciences trades under CRBU ticker.
When did Caribou Biosciences go public? Caribou Biosciences went public in 2021.
Who are competitors of Caribou Biosciences? Similar companies to Caribou Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Caribou Biosciences? Caribou Biosciences's current market cap is $74.4M
What is the current revenue of Caribou Biosciences? Caribou Biosciences's last 12-month revenue is $9.7M.
What is the current EBITDA of Caribou Biosciences? Caribou Biosciences's last 12-month EBITDA is -$167M.
What is the current EV/Revenue multiple of Caribou Biosciences? Current revenue multiple of Caribou Biosciences is -11.1x.
What is the current EV/EBITDA multiple of Caribou Biosciences? Current EBITDA multiple of Caribou Biosciences is 0.6x.
What is the current revenue growth of Caribou Biosciences? Caribou Biosciences revenue growth between 2023 and 2024 was -71%.
Is Caribou Biosciences profitable? Yes, Caribou Biosciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.